Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Safety, efficacy and effectiveness of delabeling in patients with multiple drug allergy labels

Vethody, C., Yu, R., Keck, J.M., Onasch, M.K., Stone, C.A. and Phillips, E.J. (2020) Safety, efficacy and effectiveness of delabeling in patients with multiple drug allergy labels. The Journal of Allergy and Clinical Immunology: In Practice . In Press.

PDF - Authors' Version
Embargoed until September 2021.

Link to Published Version:
*Subscription may be required


Patients with multiple drug allergy labels (MDAL) present a challenging barrier to patient care.

To assess the efficacy, safety and effectiveness of removing MDAL in a single clinic visit.

Retrospective chart review was performed from October 1, 2014 to October 31, 2018 on MDAL patients who had electronic health record (EHR) allergy label to two or more drug and who were delabeled to ≥1 drug.. Our primary outcome was the number of allergy labels tested and removed, at a single or multiple visits. Post-visit surveys were administered to patients, their pharmacies and primary care physicians (PCP) for patients delabeled following an EHR transition from November 2, 2017 to October 31st 2018 (n=184).

Among 536 patients meeting inclusion criteria, 916/943 (97.1%) of tested allergy labels were removed from the EHR . Most patients 461/536 (86.0%) were tested, challenged and delabeled in a single visit, to ≥ 1 drug, although 134/536 (25%) still had evidence of > 1 label at one year. In surveys, 90/171 (52.6%) of responding pharmacies and 122/168 (72.6%) of PCPs contacted had removed drug labels from the EHR as a result of the recommendations from the patient’s drug allergy evaluation. Overall, 91/142 (64.1%) of MDAL patient survey respondents were willing to take the drugs to which they had been delabeled.

MDAL patients can be safely delabeled to multiple drugs in one visit, however effectiveness barriers were identified. Reinforcement of drug allergy label removal information to patients, pharmacies and primary care providers presents a targeted area for improvement.

Item Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: Elsevier
Copyright: © 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
Item Control Page Item Control Page